Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma-like carcinoma.

Yu-Min ZhongJi ChenJie JiangWen-Bin ZhouLing-Ling GaoShui-Lian ZhangWen-Qing YanYu ChenDong-Kun ZhangDan-Xia LuZhi-Yi LvZhi XieYing HuangWei-Bang GuoBin-Chao WangJin-Ji YangXue-Ning YangYi-Long WuXu-Chao Zhang

Published in: Clinical & translational immunology (2024)

Plasma EBV DNA could be a useful and easy-to-use biomarker for predicting the clinical activity of ICB in PLELC and could serve to monitor disease progression earlier than computed tomography imaging.

Keyphrases

epstein barr virus
computed tomography
diffuse large b cell lymphoma
high resolution
pulmonary hypertension
magnetic resonance imaging
positron emission tomography
circulating tumor
cell free
single molecule
magnetic resonance
contrast enhanced
nucleic acid
circulating tumor cells